ReviewCureus2025
Pancreatitis Unveiled: Linking Pathogenesis, Organ Failure, and Emerging Predictive Biomarkers.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis is an inflammatory condition that starts as a mild illness but can progress to become fatal through multi-organ failure with high death rates. The APACHE II and BISAP scoring systems help identify patient risks, but their ability to forecast early deterioration remains limited during the initial hours following admission when critical decisions need to be made. This review examines the mechanisms linking pancreatic injury to systemic inflammation and organ failure, outlining the distinction between early sterile organ failure and later sepsis-related failure. Clinical patterns of organ dysfunction correlate strongly with the inflammatory response, and early indicators such as systemic inflammatory response syndrome duration, rising blood urea nitrogen, hemoconcentration, and increasing CRP provide useful predictors of disease severity. Emerging biomarkers, including IL-6, IL-8, circulating histones, angiopoietin-2, arterial lactate, and albumin-based ratios, show promise for forecasting persistent organ failure. Integrating these markers with machine learning algorithms and multi-cytokine panels enhances predictive accuracy for patient risk assessment and early intensive care unit admission. Although promising, most of these biomarkers and AI-based tools remain investigational and require further multicenter validation. Future research should prioritize standardized assay methods and prospective evaluation of combined clinical-biomarker-AI models to determine their true impact on early diagnosis, triage, and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.